<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04240873</url>
  </required_header>
  <id_info>
    <org_study_id>KC19CNSI0469</org_study_id>
    <nct_id>NCT04240873</nct_id>
  </id_info>
  <brief_title>Clinical Study of Intra Articular Injection of Catholic MASTER Cell (Bone Marrow Derived Mesenchymal Stem Cell) in Knee Osteoarthritis</brief_title>
  <acronym>MSC-OA</acronym>
  <official_title>Randomized Double-blind Clinical Study of Intra Articular Injection of Catholic MASTER Cell in Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul St. Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul St. Mary's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. objective&#xD;
&#xD;
           - safety and efficacy evalaution of MASTER cells injected into knee of patients with&#xD;
           osteoarthritis&#xD;
&#xD;
        2. background&#xD;
&#xD;
             -  osteoarthritis&#xD;
&#xD;
                  -  Osteoarthritis is severe and intractable musculoskeletal disease that&#xD;
                     eventually leads to joint failure and pain due to inflammation and joint&#xD;
                     injury.&#xD;
&#xD;
                  -  OA is one of the most prevalent diseases. The prevalence increases with age,&#xD;
                     but overuse and trauma can result in OA in young population as well.&#xD;
&#xD;
                  -  Injured cartilage can not be regenerated spontaneously, untreated injured&#xD;
                     cartilage eventually leads to osteoarthritis. Surgical treatment may repair&#xD;
                     the damage but the reparied cartilage may turn out to be fibrocartilage rather&#xD;
                     than hyaline cartilage.&#xD;
&#xD;
             -  Curent treatment&#xD;
&#xD;
                  -  medical therapy: medication for symptom relief, together with exercise.&#xD;
                     Medications include NSAIDS visco-supplement.&#xD;
&#xD;
                  -  surgical therapy: total knee replacement arthroplasty&#xD;
&#xD;
                  -  to overcome such limitations, cell therapy such as stem cell/ chondrocyte&#xD;
                     injection is being investigated&#xD;
&#xD;
        3. Hypothesis&#xD;
&#xD;
           - Intra articular injection of MASTER cells will show safety and efficacy in terms of&#xD;
           pain and functional improvement.&#xD;
&#xD;
        4. Protocol 1) deisgn : Injection of MASTER cell 1X 10^8 cells/2cc (experimental arm) or&#xD;
           2cc saline (placebo arm) into knee of patients with osteoarthritis 2) outcomes&#xD;
&#xD;
             -  primary outcome : safety evaluation(adverse event)&#xD;
&#xD;
             -  secondary outcomes : check on 1,2,3,6,9,12 months, atient reported outcome (WOMAC,&#xD;
                KOOS, IKDC, pain VAS) 3,12 months SF-36, knee MRI score, serum cytokine, bone&#xD;
                turnover marker 12 months x-ray 3) Disease&#xD;
&#xD;
             -  osteoarthritis&#xD;
&#xD;
                4) Subjects&#xD;
&#xD;
                  1. inclusion : age 20-80yrs, diagnosed with OA according to ACR criteria for knee&#xD;
                     OA, baseline pain VAS equal or more than 50mm&#xD;
&#xD;
                  2. exclusion: lower extremities surgery within 6months or planned surgery,&#xD;
                     concommitant systemic rheumatic diseases that can affect the results of the&#xD;
                     trial, steroid intraarticular inejction into the index knee within 3months,&#xD;
                     clinicallly meaningful abnormal lab tests (liver function, kidney function)&#xD;
&#xD;
                5) evaluation&#xD;
&#xD;
             -  primary outome : compare the number and proportion of of adverse event and lab test&#xD;
                abnormalities between the two arms&#xD;
&#xD;
             -  secondary outome&#xD;
&#xD;
                  1. change of 100mm pain VAS&#xD;
&#xD;
                  2. change of Western Ontario and McMAster Universities Osteoarthritis (WOMAC)&#xD;
                     pain VAS, IKDC, KOOS total score&#xD;
&#xD;
                  3. change WOMAC sub scale, IKDC, KOOS&#xD;
&#xD;
                  4. chagne of KHAQ&#xD;
&#xD;
                  5. change of MRI indices&#xD;
&#xD;
                  6. change of x-ray( joins space narrowing)&#xD;
&#xD;
                  7. change of serum ESR/CRP, CTX-II&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>adverse event according to CTCAE 5.0, clinically meaningful abnormalites in laboratory tests (blood)</measure>
    <time_frame>Change from Baseline blood abnormalities at 12 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Western Ontario and McMaster Universities Arthritis Index (WOMAC) score</measure>
    <time_frame>Change from Baseline WOMAC score at 12 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Knee injury and Osteoarthritis Outcome Score (KOOS)</measure>
    <time_frame>Change from Baseline KOOS score at 12 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>International knee documentation committee (IKDC)</measure>
    <time_frame>Change from Baseline IKDC score at 12 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cartilage damage evaluation through knee MRI</measure>
    <time_frame>Change from Baseline cartilage morphology at 12 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SF-36 questionnaire</measure>
    <time_frame>Change from Baseline SF-36 score at 12 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum inflammatory cytokine, acute phase reactant, bone turnover marker</measure>
    <time_frame>Change from Baseline cytokine level, acute phase reactant, bone turnover marker level at 12 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cartilage damage evaluation through knee x-ray</measure>
    <time_frame>Change from Baseline cartilage and bone morphology at 12 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>MASTER cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraarticular injection of Catholic MASTER cell, 1 time, 1 x 10^8 cells/DMEM 5cc, into knee joint of patients with osteoarthritis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intraarticular injection of saline, 1 time, 5cc, into knee joint of patients with osteoarthritis</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Catholic MASTER cell</intervention_name>
    <description>Injection of CATHOLIC MASTER cells 1 x 10^8 cells/DMEM 5cc into knee of patents with osteoarthritis</description>
    <arm_group_label>MASTER cell</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Injection of saline 5cc into knee of patents with osteoarthritis</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 20-80&#xD;
&#xD;
          2. diagnosed with knee osteoarthritis (OA) according to ACR classfication criteia for&#xD;
             knee OA&#xD;
&#xD;
          3. symptomatic OA that lastede for at least 3 months before screening&#xD;
&#xD;
          4. Baseline Pain VAS â‰¥50 mm&#xD;
&#xD;
          5. treated with medication such as acetaminophen, tramadol, NSAID for at least 1month due&#xD;
             to OA pain&#xD;
&#xD;
          6. X-ray Kellgren-Lawrence grade 1~4&#xD;
&#xD;
          7. volauntarily enrolled with informed consent&#xD;
&#xD;
          8. no improvement with medical treatment for at least 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. disease in spine or lower extremities that can affect the outcome of index knee&#xD;
&#xD;
          2. surgery on lower extremities within 6month before injection or planned&#xD;
&#xD;
          3. joint symptoms that can affect the interpretation of the trial data or prevent the&#xD;
             subject from enrollement including but not limited to symptomatic fracture,&#xD;
             fibromyalgia, rheumatoid arthritis, reactive arthritis&#xD;
&#xD;
          4. steroid injection to the index knee within preivious 3months&#xD;
&#xD;
          5. hyaluronic acid injection to the index knee within preivious 6months&#xD;
&#xD;
          6. underwent cell therapy or gene therapy in the past&#xD;
&#xD;
          7. more than 3 times upper normal limit in one or more of the followings: serum&#xD;
             creatinine, bilirubin, alanine aminotransferase (ALT) or aspartate aminotransferase&#xD;
             (AST) or more than 3 times upper normal limit in two or more of the followings:&#xD;
             bilirubin, alanine aminotransferase (ALT) or aspartate aminotransferase (AST)&#xD;
&#xD;
          8. participation in a different clinical trial other than this within 4 weeks after&#xD;
             initiation of the current study&#xD;
&#xD;
          9. use (reccuent use or addiction) of substances that can affect pain sensation such as&#xD;
             narcotics&#xD;
&#xD;
         10. females of childbearing age who do not consent to effective contraceptive methods&#xD;
             during the study period&#xD;
&#xD;
         11. pregnant or lactating woman&#xD;
&#xD;
         12. malignancy&#xD;
&#xD;
         13. considered to be inappropriate for the trial by investigators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji Hyeon Ju, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ji Hyeon Ju, MD, PhD</last_name>
    <phone>82-2-2258-6893</phone>
    <email>juji@catholic.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Lee, MD, PhD</last_name>
    <phone>82-2-2258-6893</phone>
    <email>poohish@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Catholic University of Korea</name>
      <address>
        <city>Seoul</city>
        <zip>06950</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji Hyeon Ju, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>January 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul St. Mary's Hospital</investigator_affiliation>
    <investigator_full_name>Ji Hyeon Ju</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>mesenchymal stem cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

